What is the role of the microenvironment in MDS?

Laura M Calvi; Allison J Li; Michael W Becker

doi:10.1016/j.beha.2019.101113

What is the role of the microenvironment in MDS?

Best Pract Res Clin Haematol. 2019 Dec;32(4):101113. doi: 10.1016/j.beha.2019.101113. Epub 2019 Oct 28.

Authors

Laura M Calvi¹, Allison J Li², Michael W Becker²

Affiliations

¹ University of Rochester School of Medicine, Wilmot Cancer Institute, 601 Elmwood Avenue, Box 794, Rochester, NY, 14642, USA. Electronic address: Laura_calvi@urmc.rochester.edu.
² University of Rochester School of Medicine, Wilmot Cancer Institute, 601 Elmwood Avenue, Box 794, Rochester, NY, 14642, USA.

PMID: 31779976
DOI: 10.1016/j.beha.2019.101113

Abstract

Treating myelodysplastic syndromes (MDS) remains challenging. Hematopoiesis occurs within a heterogeneous, complex and dynamic microenvironment, and a multiplicity of mutations in hematopoietic stem and progenitor cells (HSPCs) lead to MDS. But is there a role for the microenvironment? Here we review experimental and conceptual arguments that support a role for the microenvironment, provide evidence for the disruption of the microenvironment in MDS, and explore microenvironmental signals that may provide a targetable and conserved vulnerability in MDS that transcend genetic heterogeneity.

Keywords: BMME; Bone abnormalities; Bone marrow microenvironment; HSC; HSPC); Hematopoietic stem and progenitor cell; Hematopoietic stem cells; MDS; Microenvironment; Myelodysplastic syndromes; Osteoblastic lineage.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Animals
Hematopoietic Stem Cells / metabolism*
Hematopoietic Stem Cells / pathology
Humans
Myelodysplastic Syndromes / metabolism*
Myelodysplastic Syndromes / pathology
Myelodysplastic Syndromes / therapy
Signal Transduction*
Stem Cell Niche*